US20010021520A1 - Antibiotic TKR459, production method, and microorganism - Google Patents
Antibiotic TKR459, production method, and microorganism Download PDFInfo
- Publication number
- US20010021520A1 US20010021520A1 US09/731,041 US73104100A US2001021520A1 US 20010021520 A1 US20010021520 A1 US 20010021520A1 US 73104100 A US73104100 A US 73104100A US 2001021520 A1 US2001021520 A1 US 2001021520A1
- Authority
- US
- United States
- Prior art keywords
- tkr459
- antibiotic
- strain
- acid
- microorganism
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- OWCIHWWFLRMJBF-UHFFFAOYSA-N antibiotic TKR459 Natural products OC(=O)CCC(O)(C)CCCCCCCCCCCCCC1OC(O)C(N)C(O)C1O OWCIHWWFLRMJBF-UHFFFAOYSA-N 0.000 title claims abstract description 15
- CULZKXGOLIWOSD-UHFFFAOYSA-N antibiotic tkr 459 Chemical compound OC(=O)CCC1(C)CCCCCCCCCCCCCC(O)C(O)C(O)C(N)C(O)O1 CULZKXGOLIWOSD-UHFFFAOYSA-N 0.000 title claims abstract description 15
- 244000005700 microbiome Species 0.000 title claims description 17
- 238000004519 manufacturing process Methods 0.000 title claims description 6
- 150000003839 salts Chemical class 0.000 claims abstract description 19
- 239000000126 substance Substances 0.000 claims abstract description 18
- 241000233866 Fungi Species 0.000 claims description 20
- 230000003115 biocidal effect Effects 0.000 claims description 10
- 239000003242 anti bacterial agent Substances 0.000 claims description 7
- 230000000843 anti-fungal effect Effects 0.000 abstract description 5
- 229940121375 antifungal agent Drugs 0.000 abstract description 5
- 239000003814 drug Substances 0.000 abstract description 5
- 208000024386 fungal infectious disease Diseases 0.000 abstract description 3
- 238000002560 therapeutic procedure Methods 0.000 abstract description 2
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 48
- 238000004128 high performance liquid chromatography Methods 0.000 description 16
- 239000002609 medium Substances 0.000 description 16
- WEVYAHXRMPXWCK-UHFFFAOYSA-N Acetonitrile Chemical compound CC#N WEVYAHXRMPXWCK-UHFFFAOYSA-N 0.000 description 10
- 230000002829 reductive effect Effects 0.000 description 10
- CSCPPACGZOOCGX-UHFFFAOYSA-N Acetone Chemical compound CC(C)=O CSCPPACGZOOCGX-UHFFFAOYSA-N 0.000 description 9
- HEDRZPFGACZZDS-UHFFFAOYSA-N Chloroform Chemical compound ClC(Cl)Cl HEDRZPFGACZZDS-UHFFFAOYSA-N 0.000 description 8
- DTQVDTLACAAQTR-UHFFFAOYSA-N Trifluoroacetic acid Chemical compound OC(=O)C(F)(F)F DTQVDTLACAAQTR-UHFFFAOYSA-N 0.000 description 8
- 238000000034 method Methods 0.000 description 8
- VLKZOEOYAKHREP-UHFFFAOYSA-N n-Hexane Chemical compound CCCCCC VLKZOEOYAKHREP-UHFFFAOYSA-N 0.000 description 8
- 239000003463 adsorbent Substances 0.000 description 7
- 239000007788 liquid Substances 0.000 description 7
- 235000015097 nutrients Nutrition 0.000 description 7
- 239000000047 product Substances 0.000 description 7
- IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 description 6
- OKTJSMMVPCPJKN-UHFFFAOYSA-N Carbon Chemical compound [C] OKTJSMMVPCPJKN-UHFFFAOYSA-N 0.000 description 6
- XEKOWRVHYACXOJ-UHFFFAOYSA-N Ethyl acetate Chemical compound CCOC(C)=O XEKOWRVHYACXOJ-UHFFFAOYSA-N 0.000 description 6
- 241000282414 Homo sapiens Species 0.000 description 6
- LRHPLDYGYMQRHN-UHFFFAOYSA-N N-Butanol Chemical compound CCCCO LRHPLDYGYMQRHN-UHFFFAOYSA-N 0.000 description 6
- 238000010521 absorption reaction Methods 0.000 description 6
- 238000000862 absorption spectrum Methods 0.000 description 6
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 6
- 229920001817 Agar Polymers 0.000 description 5
- 241001465754 Metazoa Species 0.000 description 5
- 230000009102 absorption Effects 0.000 description 5
- 239000008272 agar Substances 0.000 description 5
- 239000000284 extract Substances 0.000 description 5
- 239000000203 mixture Substances 0.000 description 5
- 229910052757 nitrogen Inorganic materials 0.000 description 5
- 239000003960 organic solvent Substances 0.000 description 5
- 239000000843 powder Substances 0.000 description 5
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 4
- NBIIXXVUZAFLBC-UHFFFAOYSA-N Phosphoric acid Chemical class OP(O)(O)=O NBIIXXVUZAFLBC-UHFFFAOYSA-N 0.000 description 4
- 229940088710 antibiotic agent Drugs 0.000 description 4
- 238000001460 carbon-13 nuclear magnetic resonance spectrum Methods 0.000 description 4
- 239000002552 dosage form Substances 0.000 description 4
- 244000053095 fungal pathogen Species 0.000 description 4
- 230000003287 optical effect Effects 0.000 description 4
- 238000000425 proton nuclear magnetic resonance spectrum Methods 0.000 description 4
- QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Chemical compound CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 description 3
- RLIMMQMMVFYZOR-UHFFFAOYSA-N CCCCC(C)(O)CCC(=O)O.CCCCCCCCCCCC1OC(O)C(N)C(O)C1O Chemical compound CCCCC(C)(O)CCC(=O)O.CCCCCCCCCCCC1OC(O)C(N)C(O)C1O RLIMMQMMVFYZOR-UHFFFAOYSA-N 0.000 description 3
- 241000222122 Candida albicans Species 0.000 description 3
- 201000007336 Cryptococcosis Diseases 0.000 description 3
- 241000221204 Cryptococcus neoformans Species 0.000 description 3
- IAZDPXIOMUYVGZ-WFGJKAKNSA-N Dimethyl sulfoxide Chemical compound [2H]C([2H])([2H])S(=O)C([2H])([2H])[2H] IAZDPXIOMUYVGZ-WFGJKAKNSA-N 0.000 description 3
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 3
- 244000285963 Kluyveromyces fragilis Species 0.000 description 3
- 235000014663 Kluyveromyces fragilis Nutrition 0.000 description 3
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 3
- 239000002585 base Substances 0.000 description 3
- 229940095731 candida albicans Drugs 0.000 description 3
- 229910052799 carbon Inorganic materials 0.000 description 3
- KRKNYBCHXYNGOX-UHFFFAOYSA-N citric acid Chemical compound OC(=O)CC(O)(C(O)=O)CC(O)=O KRKNYBCHXYNGOX-UHFFFAOYSA-N 0.000 description 3
- 239000003086 colorant Substances 0.000 description 3
- -1 etc. Chemical class 0.000 description 3
- 238000000605 extraction Methods 0.000 description 3
- 239000008103 glucose Substances 0.000 description 3
- 230000002401 inhibitory effect Effects 0.000 description 3
- 238000002955 isolation Methods 0.000 description 3
- 125000004433 nitrogen atom Chemical group N* 0.000 description 3
- 239000008194 pharmaceutical composition Substances 0.000 description 3
- 238000000746 purification Methods 0.000 description 3
- 239000007787 solid Substances 0.000 description 3
- 239000002904 solvent Substances 0.000 description 3
- 206010052366 systemic mycosis Diseases 0.000 description 3
- YBJHBAHKTGYVGT-ZKWXMUAHSA-N (+)-Biotin Chemical compound N1C(=O)N[C@@H]2[C@H](CCCCC(=O)O)SC[C@@H]21 YBJHBAHKTGYVGT-ZKWXMUAHSA-N 0.000 description 2
- OYPRJOBELJOOCE-UHFFFAOYSA-N Calcium Chemical class [Ca] OYPRJOBELJOOCE-UHFFFAOYSA-N 0.000 description 2
- 241000222120 Candida <Saccharomycetales> Species 0.000 description 2
- IAZDPXIOMUYVGZ-UHFFFAOYSA-N Dimethylsulphoxide Chemical compound CS(C)=O IAZDPXIOMUYVGZ-UHFFFAOYSA-N 0.000 description 2
- 241000196324 Embryophyta Species 0.000 description 2
- KRHYYFGTRYWZRS-UHFFFAOYSA-N Fluorane Chemical compound F KRHYYFGTRYWZRS-UHFFFAOYSA-N 0.000 description 2
- VZCYOOQTPOCHFL-OWOJBTEDSA-N Fumaric acid Chemical compound OC(=O)\C=C\C(O)=O VZCYOOQTPOCHFL-OWOJBTEDSA-N 0.000 description 2
- 206010017533 Fungal infection Diseases 0.000 description 2
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 2
- DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical class C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 description 2
- AFVFQIVMOAPDHO-UHFFFAOYSA-N Methanesulfonic acid Chemical compound CS(O)(=O)=O AFVFQIVMOAPDHO-UHFFFAOYSA-N 0.000 description 2
- 208000031888 Mycoses Diseases 0.000 description 2
- ZLMJMSJWJFRBEC-UHFFFAOYSA-N Potassium Chemical class [K] ZLMJMSJWJFRBEC-UHFFFAOYSA-N 0.000 description 2
- 240000004808 Saccharomyces cerevisiae Species 0.000 description 2
- QAOWNCQODCNURD-UHFFFAOYSA-N Sulfuric acid Chemical compound OS(O)(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-N 0.000 description 2
- XSQUKJJJFZCRTK-UHFFFAOYSA-N Urea Chemical compound NC(N)=O XSQUKJJJFZCRTK-UHFFFAOYSA-N 0.000 description 2
- 229910000147 aluminium phosphate Inorganic materials 0.000 description 2
- 239000007864 aqueous solution Substances 0.000 description 2
- 239000011575 calcium Chemical class 0.000 description 2
- 229910052791 calcium Inorganic materials 0.000 description 2
- 230000018842 conidium formation Effects 0.000 description 2
- 239000000287 crude extract Substances 0.000 description 2
- 238000005516 engineering process Methods 0.000 description 2
- 238000004992 fast atom bombardment mass spectroscopy Methods 0.000 description 2
- 239000000945 filler Substances 0.000 description 2
- 238000009472 formulation Methods 0.000 description 2
- 239000000499 gel Substances 0.000 description 2
- 230000005764 inhibitory process Effects 0.000 description 2
- JVTAAEKCZFNVCJ-UHFFFAOYSA-N lactic acid Chemical compound CC(O)C(O)=O JVTAAEKCZFNVCJ-UHFFFAOYSA-N 0.000 description 2
- 238000004949 mass spectrometry Methods 0.000 description 2
- BDAGIHXWWSANSR-UHFFFAOYSA-N methanoic acid Natural products OC=O BDAGIHXWWSANSR-UHFFFAOYSA-N 0.000 description 2
- 210000000214 mouth Anatomy 0.000 description 2
- 231100000252 nontoxic Toxicity 0.000 description 2
- 230000003000 nontoxic effect Effects 0.000 description 2
- 150000007524 organic acids Chemical class 0.000 description 2
- 235000005985 organic acids Nutrition 0.000 description 2
- 239000011591 potassium Chemical class 0.000 description 2
- 229910052700 potassium Inorganic materials 0.000 description 2
- 239000011347 resin Substances 0.000 description 2
- 229920005989 resin Polymers 0.000 description 2
- 238000011218 seed culture Methods 0.000 description 2
- 239000000741 silica gel Substances 0.000 description 2
- 229910002027 silica gel Inorganic materials 0.000 description 2
- 229910052708 sodium Inorganic materials 0.000 description 2
- 239000011734 sodium Substances 0.000 description 2
- 239000000243 solution Substances 0.000 description 2
- 238000001228 spectrum Methods 0.000 description 2
- 201000009862 superficial mycosis Diseases 0.000 description 2
- 239000004094 surface-active agent Substances 0.000 description 2
- 239000000725 suspension Substances 0.000 description 2
- 229940124597 therapeutic agent Drugs 0.000 description 2
- 229940126585 therapeutic drug Drugs 0.000 description 2
- VZCYOOQTPOCHFL-UHFFFAOYSA-N trans-butenedioic acid Natural products OC(=O)C=CC(O)=O VZCYOOQTPOCHFL-UHFFFAOYSA-N 0.000 description 2
- 235000013311 vegetables Nutrition 0.000 description 2
- MIOPJNTWMNEORI-GMSGAONNSA-N (S)-camphorsulfonic acid Chemical compound C1C[C@@]2(CS(O)(=O)=O)C(=O)C[C@@H]1C2(C)C MIOPJNTWMNEORI-GMSGAONNSA-N 0.000 description 1
- 238000001644 13C nuclear magnetic resonance spectroscopy Methods 0.000 description 1
- 238000005160 1H NMR spectroscopy Methods 0.000 description 1
- LBLYYCQCTBFVLH-UHFFFAOYSA-N 2-Methylbenzenesulfonic acid Chemical compound CC1=CC=CC=C1S(O)(=O)=O LBLYYCQCTBFVLH-UHFFFAOYSA-N 0.000 description 1
- BMYNFMYTOJXKLE-UHFFFAOYSA-N 3-azaniumyl-2-hydroxypropanoate Chemical compound NCC(O)C(O)=O BMYNFMYTOJXKLE-UHFFFAOYSA-N 0.000 description 1
- OSWFIVFLDKOXQC-UHFFFAOYSA-N 4-(3-methoxyphenyl)aniline Chemical compound COC1=CC=CC(C=2C=CC(N)=CC=2)=C1 OSWFIVFLDKOXQC-UHFFFAOYSA-N 0.000 description 1
- RJBSTXIIQYFNPX-UHFFFAOYSA-N 4-methoxy-6-phenyl-1,3,5-triazin-2-amine Chemical compound COC1=NC(N)=NC(C=2C=CC=CC=2)=N1 RJBSTXIIQYFNPX-UHFFFAOYSA-N 0.000 description 1
- APKFDSVGJQXUKY-KKGHZKTASA-N Amphotericin-B Natural products O[C@H]1[C@@H](N)[C@H](O)[C@@H](C)O[C@H]1O[C@H]1C=CC=CC=CC=CC=CC=CC=C[C@H](C)[C@@H](O)[C@@H](C)[C@H](C)OC(=O)C[C@H](O)C[C@H](O)CC[C@@H](O)[C@H](O)C[C@H](O)C[C@](O)(C[C@H](O)[C@H]2C(O)=O)O[C@H]2C1 APKFDSVGJQXUKY-KKGHZKTASA-N 0.000 description 1
- 241000228212 Aspergillus Species 0.000 description 1
- DKPFZGUDAPQIHT-UHFFFAOYSA-N Butyl acetate Natural products CCCCOC(C)=O DKPFZGUDAPQIHT-UHFFFAOYSA-N 0.000 description 1
- 208000035473 Communicable disease Diseases 0.000 description 1
- 229920000742 Cotton Polymers 0.000 description 1
- 241001337994 Cryptococcus <scale insect> Species 0.000 description 1
- 239000004375 Dextrin Substances 0.000 description 1
- 229920001353 Dextrin Polymers 0.000 description 1
- FEWJPZIEWOKRBE-JCYAYHJZSA-N Dextrotartaric acid Chemical compound OC(=O)[C@H](O)[C@@H](O)C(O)=O FEWJPZIEWOKRBE-JCYAYHJZSA-N 0.000 description 1
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 1
- 229930091371 Fructose Natural products 0.000 description 1
- 239000005715 Fructose Substances 0.000 description 1
- RFSUNEUAIZKAJO-ARQDHWQXSA-N Fructose Chemical compound OC[C@H]1O[C@](O)(CO)[C@@H](O)[C@@H]1O RFSUNEUAIZKAJO-ARQDHWQXSA-N 0.000 description 1
- 241000282412 Homo Species 0.000 description 1
- UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 description 1
- 238000004566 IR spectroscopy Methods 0.000 description 1
- FYYHWMGAXLPEAU-UHFFFAOYSA-N Magnesium Chemical class [Mg] FYYHWMGAXLPEAU-UHFFFAOYSA-N 0.000 description 1
- NTIZESTWPVYFNL-UHFFFAOYSA-N Methyl isobutyl ketone Chemical compound CC(C)CC(C)=O NTIZESTWPVYFNL-UHFFFAOYSA-N 0.000 description 1
- UIHCLUNTQKBZGK-UHFFFAOYSA-N Methyl isobutyl ketone Natural products CCC(C)C(C)=O UIHCLUNTQKBZGK-UHFFFAOYSA-N 0.000 description 1
- BYBLEWFAAKGYCD-UHFFFAOYSA-N Miconazole Chemical compound ClC1=CC(Cl)=CC=C1COC(C=1C(=CC(Cl)=CC=1)Cl)CN1C=NC=C1 BYBLEWFAAKGYCD-UHFFFAOYSA-N 0.000 description 1
- 241000699670 Mus sp. Species 0.000 description 1
- GXCLVBGFBYZDAG-UHFFFAOYSA-N N-[2-(1H-indol-3-yl)ethyl]-N-methylprop-2-en-1-amine Chemical compound CN(CCC1=CNC2=C1C=CC=C2)CC=C GXCLVBGFBYZDAG-UHFFFAOYSA-N 0.000 description 1
- 238000005481 NMR spectroscopy Methods 0.000 description 1
- GRYLNZFGIOXLOG-UHFFFAOYSA-N Nitric acid Chemical compound O[N+]([O-])=O GRYLNZFGIOXLOG-UHFFFAOYSA-N 0.000 description 1
- UULYVBBLIYLRCU-UHFFFAOYSA-N Palmitinsaeure-n-tetradecylester Natural products CCCCCCCCCCCCCCCC(=O)OCCCCCCCCCCCCCC UULYVBBLIYLRCU-UHFFFAOYSA-N 0.000 description 1
- 239000001888 Peptone Substances 0.000 description 1
- 108010080698 Peptones Proteins 0.000 description 1
- 239000002202 Polyethylene glycol Substances 0.000 description 1
- OFOBLEOULBTSOW-UHFFFAOYSA-N Propanedioic acid Natural products OC(=O)CC(O)=O OFOBLEOULBTSOW-UHFFFAOYSA-N 0.000 description 1
- 239000006159 Sabouraud's agar Substances 0.000 description 1
- 244000061456 Solanum tuberosum Species 0.000 description 1
- 235000002595 Solanum tuberosum Nutrition 0.000 description 1
- 235000019764 Soybean Meal Nutrition 0.000 description 1
- 229920002472 Starch Polymers 0.000 description 1
- KDYFGRWQOYBRFD-UHFFFAOYSA-N Succinic acid Natural products OC(=O)CCC(O)=O KDYFGRWQOYBRFD-UHFFFAOYSA-N 0.000 description 1
- 229930006000 Sucrose Natural products 0.000 description 1
- CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 description 1
- FEWJPZIEWOKRBE-UHFFFAOYSA-N Tartaric acid Natural products [H+].[H+].[O-]C(=O)C(O)C(O)C([O-])=O FEWJPZIEWOKRBE-UHFFFAOYSA-N 0.000 description 1
- 244000299461 Theobroma cacao Species 0.000 description 1
- 235000005764 Theobroma cacao ssp. cacao Nutrition 0.000 description 1
- 235000005767 Theobroma cacao ssp. sphaerocarpum Nutrition 0.000 description 1
- 241000223238 Trichophyton Species 0.000 description 1
- 241000209140 Triticum Species 0.000 description 1
- 235000021307 Triticum Nutrition 0.000 description 1
- 240000008042 Zea mays Species 0.000 description 1
- 235000005824 Zea mays ssp. parviglumis Nutrition 0.000 description 1
- 235000002017 Zea mays subsp mays Nutrition 0.000 description 1
- 238000002835 absorbance Methods 0.000 description 1
- 239000002250 absorbent Substances 0.000 description 1
- 230000002745 absorbent Effects 0.000 description 1
- 235000011054 acetic acid Nutrition 0.000 description 1
- 239000002253 acid Substances 0.000 description 1
- 150000007513 acids Chemical class 0.000 description 1
- 239000004480 active ingredient Substances 0.000 description 1
- 229910052783 alkali metal Inorganic materials 0.000 description 1
- 150000001340 alkali metals Chemical class 0.000 description 1
- 229910052784 alkaline earth metal Inorganic materials 0.000 description 1
- 150000001342 alkaline earth metals Chemical class 0.000 description 1
- PNEYBMLMFCGWSK-UHFFFAOYSA-N aluminium oxide Inorganic materials [O-2].[O-2].[O-2].[Al+3].[Al+3] PNEYBMLMFCGWSK-UHFFFAOYSA-N 0.000 description 1
- 150000001413 amino acids Chemical class 0.000 description 1
- 150000003863 ammonium salts Chemical class 0.000 description 1
- APKFDSVGJQXUKY-INPOYWNPSA-N amphotericin B Chemical compound O[C@H]1[C@@H](N)[C@H](O)[C@@H](C)O[C@H]1O[C@H]1/C=C/C=C/C=C/C=C/C=C/C=C/C=C/[C@H](C)[C@@H](O)[C@@H](C)[C@H](C)OC(=O)C[C@H](O)C[C@H](O)CC[C@@H](O)[C@H](O)C[C@H](O)C[C@](O)(C[C@H](O)[C@H]2C(O)=O)O[C@H]2C1 APKFDSVGJQXUKY-INPOYWNPSA-N 0.000 description 1
- 229960003942 amphotericin b Drugs 0.000 description 1
- 238000004458 analytical method Methods 0.000 description 1
- 230000000845 anti-microbial effect Effects 0.000 description 1
- 230000001857 anti-mycotic effect Effects 0.000 description 1
- 239000003429 antifungal agent Substances 0.000 description 1
- 239000002543 antimycotic Substances 0.000 description 1
- 239000012736 aqueous medium Substances 0.000 description 1
- 244000052616 bacterial pathogen Species 0.000 description 1
- SRSXLGNVWSONIS-UHFFFAOYSA-N benzenesulfonic acid Chemical compound OS(=O)(=O)C1=CC=CC=C1 SRSXLGNVWSONIS-UHFFFAOYSA-N 0.000 description 1
- 229940092714 benzenesulfonic acid Drugs 0.000 description 1
- WQZGKKKJIJFFOK-VFUOTHLCSA-N beta-D-glucose Chemical compound OC[C@H]1O[C@@H](O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-VFUOTHLCSA-N 0.000 description 1
- 230000004071 biological effect Effects 0.000 description 1
- 230000005540 biological transmission Effects 0.000 description 1
- 235000020958 biotin Nutrition 0.000 description 1
- 239000011616 biotin Substances 0.000 description 1
- 229960002685 biotin Drugs 0.000 description 1
- 230000037396 body weight Effects 0.000 description 1
- 210000004556 brain Anatomy 0.000 description 1
- KDYFGRWQOYBRFD-NUQCWPJISA-N butanedioic acid Chemical compound O[14C](=O)CC[14C](O)=O KDYFGRWQOYBRFD-NUQCWPJISA-N 0.000 description 1
- 235000014121 butter Nutrition 0.000 description 1
- 235000001046 cacaotero Nutrition 0.000 description 1
- 229940041514 candida albicans extract Drugs 0.000 description 1
- 239000002775 capsule Substances 0.000 description 1
- 239000004202 carbamide Substances 0.000 description 1
- 150000001721 carbon Chemical group 0.000 description 1
- 125000004432 carbon atom Chemical group C* 0.000 description 1
- 239000000969 carrier Substances 0.000 description 1
- 239000005018 casein Substances 0.000 description 1
- BECPQYXYKAMYBN-UHFFFAOYSA-N casein, tech. Chemical compound NCCCCC(C(O)=O)N=C(O)C(CC(O)=O)N=C(O)C(CCC(O)=N)N=C(O)C(CC(C)C)N=C(O)C(CCC(O)=O)N=C(O)C(CC(O)=O)N=C(O)C(CCC(O)=O)N=C(O)C(C(C)O)N=C(O)C(CCC(O)=N)N=C(O)C(CCC(O)=N)N=C(O)C(CCC(O)=N)N=C(O)C(CCC(O)=O)N=C(O)C(CCC(O)=O)N=C(O)C(COP(O)(O)=O)N=C(O)C(CCC(O)=N)N=C(O)C(N)CC1=CC=CC=C1 BECPQYXYKAMYBN-UHFFFAOYSA-N 0.000 description 1
- 235000021240 caseins Nutrition 0.000 description 1
- 238000005119 centrifugation Methods 0.000 description 1
- 238000012512 characterization method Methods 0.000 description 1
- 235000015165 citric acid Nutrition 0.000 description 1
- 150000001868 cobalt Chemical class 0.000 description 1
- 238000004440 column chromatography Methods 0.000 description 1
- 150000001875 compounds Chemical class 0.000 description 1
- 238000011109 contamination Methods 0.000 description 1
- 238000007796 conventional method Methods 0.000 description 1
- 150000001879 copper Chemical class 0.000 description 1
- 235000005822 corn Nutrition 0.000 description 1
- 239000006071 cream Substances 0.000 description 1
- 238000012258 culturing Methods 0.000 description 1
- 238000001514 detection method Methods 0.000 description 1
- 235000019425 dextrin Nutrition 0.000 description 1
- 239000008121 dextrose Substances 0.000 description 1
- 235000013681 dietary sucrose Nutrition 0.000 description 1
- 239000003085 diluting agent Substances 0.000 description 1
- 238000003113 dilution method Methods 0.000 description 1
- 201000010099 disease Diseases 0.000 description 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 1
- 239000008298 dragée Substances 0.000 description 1
- 239000006196 drop Substances 0.000 description 1
- 229940079593 drug Drugs 0.000 description 1
- 230000000694 effects Effects 0.000 description 1
- 239000003480 eluent Substances 0.000 description 1
- 238000010828 elution Methods 0.000 description 1
- 239000003974 emollient agent Substances 0.000 description 1
- 150000002148 esters Chemical class 0.000 description 1
- CCIVGXIOQKPBKL-UHFFFAOYSA-M ethanesulfonate Chemical compound CCS([O-])(=O)=O CCIVGXIOQKPBKL-UHFFFAOYSA-M 0.000 description 1
- 238000001914 filtration Methods 0.000 description 1
- 229960004884 fluconazole Drugs 0.000 description 1
- RFHAOTPXVQNOHP-UHFFFAOYSA-N fluconazole Chemical compound C1=NC=NN1CC(C=1C(=CC(F)=CC=1)F)(O)CN1C=NC=N1 RFHAOTPXVQNOHP-UHFFFAOYSA-N 0.000 description 1
- 229960004413 flucytosine Drugs 0.000 description 1
- XRECTZIEBJDKEO-UHFFFAOYSA-N flucytosine Chemical compound NC1=NC(=O)NC=C1F XRECTZIEBJDKEO-UHFFFAOYSA-N 0.000 description 1
- 235000019253 formic acid Nutrition 0.000 description 1
- 239000001530 fumaric acid Substances 0.000 description 1
- 235000011087 fumaric acid Nutrition 0.000 description 1
- 235000011187 glycerol Nutrition 0.000 description 1
- 231100001261 hazardous Toxicity 0.000 description 1
- 229910001385 heavy metal Inorganic materials 0.000 description 1
- FUZZWVXGSFPDMH-UHFFFAOYSA-N hexanoic acid Chemical compound CCCCCC(O)=O FUZZWVXGSFPDMH-UHFFFAOYSA-N 0.000 description 1
- 239000003906 humectant Substances 0.000 description 1
- 230000002209 hydrophobic effect Effects 0.000 description 1
- 238000011534 incubation Methods 0.000 description 1
- 208000015181 infectious disease Diseases 0.000 description 1
- 238000002329 infrared spectrum Methods 0.000 description 1
- 239000007924 injection Substances 0.000 description 1
- 238000002347 injection Methods 0.000 description 1
- 238000011081 inoculation Methods 0.000 description 1
- 229910052500 inorganic mineral Inorganic materials 0.000 description 1
- 238000007918 intramuscular administration Methods 0.000 description 1
- 238000007912 intraperitoneal administration Methods 0.000 description 1
- 238000001990 intravenous administration Methods 0.000 description 1
- 159000000014 iron salts Chemical class 0.000 description 1
- 239000004310 lactic acid Substances 0.000 description 1
- 235000014655 lactic acid Nutrition 0.000 description 1
- 238000009630 liquid culture Methods 0.000 description 1
- 239000008297 liquid dosage form Substances 0.000 description 1
- 238000000622 liquid--liquid extraction Methods 0.000 description 1
- 239000011777 magnesium Chemical class 0.000 description 1
- 229910052749 magnesium Inorganic materials 0.000 description 1
- 230000014759 maintenance of location Effects 0.000 description 1
- VZCYOOQTPOCHFL-UPHRSURJSA-N maleic acid Chemical compound OC(=O)\C=C/C(O)=O VZCYOOQTPOCHFL-UPHRSURJSA-N 0.000 description 1
- 239000011976 maleic acid Substances 0.000 description 1
- 235000020429 malt syrup Nutrition 0.000 description 1
- 238000001819 mass spectrum Methods 0.000 description 1
- 235000012054 meals Nutrition 0.000 description 1
- 235000013372 meat Nutrition 0.000 description 1
- 238000002844 melting Methods 0.000 description 1
- 229940098779 methanesulfonic acid Drugs 0.000 description 1
- 229960002509 miconazole Drugs 0.000 description 1
- 239000011707 mineral Substances 0.000 description 1
- 238000002156 mixing Methods 0.000 description 1
- 235000013379 molasses Nutrition 0.000 description 1
- PSZYNBSKGUBXEH-UHFFFAOYSA-N naphthalene-1-sulfonic acid Chemical compound C1=CC=C2C(S(=O)(=O)O)=CC=CC2=C1 PSZYNBSKGUBXEH-UHFFFAOYSA-N 0.000 description 1
- 229910017604 nitric acid Inorganic materials 0.000 description 1
- QJGQUHMNIGDVPM-UHFFFAOYSA-N nitrogen group Chemical group [N] QJGQUHMNIGDVPM-UHFFFAOYSA-N 0.000 description 1
- 238000010899 nucleation Methods 0.000 description 1
- 125000002347 octyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])[H] 0.000 description 1
- 235000014593 oils and fats Nutrition 0.000 description 1
- 239000002674 ointment Substances 0.000 description 1
- 239000002420 orchard Substances 0.000 description 1
- 238000007911 parenteral administration Methods 0.000 description 1
- 230000036961 partial effect Effects 0.000 description 1
- 238000005192 partition Methods 0.000 description 1
- 239000006072 paste Substances 0.000 description 1
- 235000019319 peptone Nutrition 0.000 description 1
- 239000002304 perfume Substances 0.000 description 1
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 description 1
- 229920001521 polyalkylene glycol ether Polymers 0.000 description 1
- 229920001223 polyethylene glycol Polymers 0.000 description 1
- 229920000642 polymer Polymers 0.000 description 1
- 239000001965 potato dextrose agar Substances 0.000 description 1
- 238000002360 preparation method Methods 0.000 description 1
- 239000003755 preservative agent Substances 0.000 description 1
- 230000002335 preservative effect Effects 0.000 description 1
- 230000002265 prevention Effects 0.000 description 1
- 238000004007 reversed phase HPLC Methods 0.000 description 1
- 230000002441 reversible effect Effects 0.000 description 1
- 239000012449 sabouraud dextrose agar Substances 0.000 description 1
- 238000010898 silica gel chromatography Methods 0.000 description 1
- 229920002545 silicone oil Polymers 0.000 description 1
- 210000003491 skin Anatomy 0.000 description 1
- 239000002689 soil Substances 0.000 description 1
- 239000004455 soybean meal Substances 0.000 description 1
- 238000002798 spectrophotometry method Methods 0.000 description 1
- 230000002269 spontaneous effect Effects 0.000 description 1
- 239000003381 stabilizer Substances 0.000 description 1
- 239000008107 starch Substances 0.000 description 1
- 235000019698 starch Nutrition 0.000 description 1
- 125000004079 stearyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])[H] 0.000 description 1
- 230000001954 sterilising effect Effects 0.000 description 1
- 239000006190 sub-lingual tablet Substances 0.000 description 1
- 238000007920 subcutaneous administration Methods 0.000 description 1
- 229960004793 sucrose Drugs 0.000 description 1
- 239000006228 supernatant Substances 0.000 description 1
- 239000000829 suppository Substances 0.000 description 1
- 239000003826 tablet Substances 0.000 description 1
- 239000011975 tartaric acid Substances 0.000 description 1
- 235000002906 tartaric acid Nutrition 0.000 description 1
- DPJRMOMPQZCRJU-UHFFFAOYSA-M thiamine hydrochloride Chemical compound Cl.[Cl-].CC1=C(CCO)SC=[N+]1CC1=CN=C(C)N=C1N DPJRMOMPQZCRJU-UHFFFAOYSA-M 0.000 description 1
- 238000011200 topical administration Methods 0.000 description 1
- 239000006208 topical dosage form Substances 0.000 description 1
- 230000000699 topical effect Effects 0.000 description 1
- 231100000331 toxic Toxicity 0.000 description 1
- 230000002588 toxic effect Effects 0.000 description 1
- 231100000721 toxic potential Toxicity 0.000 description 1
- 238000002211 ultraviolet spectrum Methods 0.000 description 1
- 210000001215 vagina Anatomy 0.000 description 1
- 210000001835 viscera Anatomy 0.000 description 1
- 239000011782 vitamin Substances 0.000 description 1
- 235000013343 vitamin Nutrition 0.000 description 1
- 229940088594 vitamin Drugs 0.000 description 1
- 229930003231 vitamin Natural products 0.000 description 1
- 239000011691 vitamin B1 Substances 0.000 description 1
- 239000012138 yeast extract Substances 0.000 description 1
- 150000003751 zinc Chemical class 0.000 description 1
Images
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D313/00—Heterocyclic compounds containing rings of more than six members having one oxygen atom as the only ring hetero atom
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12P—FERMENTATION OR ENZYME-USING PROCESSES TO SYNTHESISE A DESIRED CHEMICAL COMPOUND OR COMPOSITION OR TO SEPARATE OPTICAL ISOMERS FROM A RACEMIC MIXTURE
- C12P17/00—Preparation of heterocyclic carbon compounds with only O, N, S, Se or Te as ring hetero atoms
- C12P17/02—Oxygen as only ring hetero atoms
- C12P17/08—Oxygen as only ring hetero atoms containing a hetero ring of at least seven ring members, e.g. zearalenone, macrolide aglycons
Definitions
- the present invention relates to TKR459, which is an antibiotic of use as a therapeutic agent for fungal infectious diseases, a method for their production, and microorganisms producing said antibiotic.
- Fungi are known to cause a variety of infectious diseases in man, animals, and plants. In man, for instance, they cause superficial mycosis affecting the skin, oral cavity, etc. and systemicmycosis affecting the viscera, brain, etc. They cause similar infections in pet and domestic animals as well. Furthermore, fungi inflict various hazardous effects on plants such as orchard trees and vegetables.
- Candida As the principal pathogenic fungi causing systemic mycosis in man, those of the genera Candida, Cryptococcus, and Aspergillus, among others, are known. As to superficial mycosis, Candida species affecting the skin, oral cavity, and vagina and Trichophytons infecting the skin of the extremities are regarded as the major pathogenic fungi. Besides those fungi, many other fungi exist in the environment and are suspected to contaminate the animal and vegetable kingdoms.
- the present invention has for its object to provide a novel antibiotic which is of value as a therapeutic agent for fungal infections.
- the inventors of the present invention isolated a large number of microorganisms from the natural kingdom, isolated the antibiotics they produced, and scrutinized their biological properties. As a result, they discovered that the culture broth of a strain of microorganism of the class Fungi Imperfecti contained an antibiotic having antifungal activity against pathogenic fungi inclusive of Candida albicans, Candida kefyr , and Cryptococcus neoformans . Accordingly the inventors isolated this antibiotic and studied its physicochemical properties. As a result, they discovered that the above antibiotic is a novel substance having distinct physicochemical characteristics and named it TKR459.
- the present invention is directed to the novel antibiotic TKR459 which is represented by the following chemical formula (1), or its pharmacologically acceptable salt.
- the present invention is further directed to a method of producing the antibiotic TKR459 which comprises culturing a strain of microorganism belonging to Fungi Imperfecti and capable of elaborating said antibiotic TKR459 and then isolating said substance from the resulting culture broth.
- the present invention is directed to a microorganism belonging to Fungi Imperfecti and capable of producing the antibiotic TKR459.
- FIG. 1 is a chart showing the ultraviolet absorption spectrum of the antibiotic TKR459. The ordinate represents wave length (nm) and the abscissa represents absorbance.
- FIG. 2 is a chart showing the infrared absorption spectrum of the antibiotic TKR459. The ordinate represents relative intensity of transmission (%) and the abscissa represents wave numbers (cm ⁇ 1 ).
- FIG. 3 is a chart showing the 1 H-NMR spectrum of the antibiotic TKR459.
- the ordiante represents intensity of signal and the abscissa represents chemical shift value (ppm).
- FIG. 4 is a chart showing the 13 C-NMR spectrum of the antibiotic TKR459.
- the ordiante represents intensity of signal and the abscissa represents chemical shift value (ppm).
- FIG. 5 is a HPLC chart of the antibiotic TKR459 showing its elution position. The ordinate represents the relative intensity of ultraviolet absorption and the abscissa represents retention time (min.).
- the antibiotic TKR459 of the present invention is represented by the chemical formula (1) described above.
- the antibiotic TKR459 has the following physicochemical characteristics (1), (2), (3), (4), (5) and (6).
- the wave numebers of major absorption in the IR spectrum by KBr method are 3400 cm ⁇ , 2920 cm ⁇ , 2850 cm ⁇ , 1680 cm ⁇ 1 , 1470 cm ⁇ , 1200 cm ⁇ , 1140 cm ⁇ , 840 cm ⁇ , 800 cm ⁇ , and 720 cm ⁇ .
- TKR459 mentioned above is characterized in that it has the 1 H-NMR spectrum shown in FIG. 3 and the 13 C-NMR spectrum shown in FIG. 4, and in reversed-phase high- performance liquid chromatography, it is eluted at the position indicated in FIG. 5.
- the above-mentioned TKR459 can be produced by growing a strain of microorganism belonging to the class Fungi Imperfecti and capable of producing said TKR459 and then isolating the substance from the resulting culture broth.
- the strain of microorganism that can be used in the present invention only provided it belongs to the class Fungi Imperfecti and is capable of producing said TKR459.
- the fungi TKR459-strain belonging to the class Fungi Imperfecti (hereinafter referred to as the TKR459-strain) can be mentioned.
- TKR459-strain is a novel strain, and has never described in literatures, and isolated and characterized for the first time by the inventors of the present invention.
- the strain has the property to produce TKR459 with advantage.
- the mycological characteristics of this TKR459-strain are now described in detail.
- the above TKR459-strain grows slowly on malt extract agar, potato dextrose agar, and Sabouraud agar etc., giving colonies showing a ropy or velvety surface texture and a elevated center with dense hard mycelia.
- the conidia of the TKR459-strain are unicellar, have a shape like cylinder or cask whose both sides are round and surface is smooth, and measure 4 to 6 ⁇ 1.5 to 2.5 ⁇ m. Lots of conidia are formed or the above media, but the conidia formation style from the conidiophore was unidentified.
- Temperature range for growth The temperature range for growth is 10 to 30° C. and the optimum range of temperature for growth is about 25° C.
- the pH range for growth is pH 3 to 8 and the optimum range of pH for growth is about pH 4 to 7.
- the present invention can be carried into practice not only with the above-mentioned TKR459-strain but also with any spontaneous or artificial mutant of said TKR459-strain or any other strain of microorganism belonging to the class Fungi Imperfecti and capable of producing TKR459.
- TKR459 is produced by seeding and cultivating a TKR459-producing strain in a nutrient medium.
- carbon sources include glucose, fructose, saccharose, starch, dextrin, glycerol, molasses, malt syrup, oils and fats, and organic acids.
- Nitrogen sources as nutrients include organic and inorganic nitrogenous substances such as soybean meal, cotton seed meal, corn steep liquor, casein, peptone, yeast extract, meat extract, wheat germs, urea, amino acids, ammonium salts, etc.
- Salts as nutrients are various inorganic salts such as salts of sodium, potassium, calcium, magnesium, etc. and salts of phosphoric acid. Those substances can be used independently or in a suitable combination.
- the nutrient medium may be supplemented with heavy metal salts such as iron salts, copper salts, zinc salts, cobalt salts, etc., vitamins such as biotin, vitamin B 1 , etc., and other organic and inorganic substances which would assist in growth of the microorganism and promote production of TKR459.
- heavy metal salts such as iron salts, copper salts, zinc salts, cobalt salts, etc.
- vitamins such as biotin, vitamin B 1 , etc.
- other organic and inorganic substances which would assist in growth of the microorganism and promote production of TKR459.
- an antifoamer and/or a surfactant for example silicone oil, polyalkylene glycol ethers, etc., can be added to the nutrient medium.
- the cultivation is preferably carried out at 15 to 25%.
- the pH of the medium may range from pH 3 to 8 but is preferably around pH 5.
- a sufficient output of the antibiotic can be expected by 6 to 11 days of culture.
- TKR459 is contained both intracellularly and extracellularly and accumulated in the culture broth.
- the TKR459 accumulated in the culture broth can be recovered and isolated from the broth by utilizing its physicochemical characteristics and, where necessary, by further purification.
- the above-mentioned isolation can be achieved by extracting the whole broth with a non-hydrophilic organic solvent such as ethyl acetate, butyl acetate, chloroform, butanol, methyl isobutyl ketone, or the like.
- a non-hydrophilic organic solvent such as ethyl acetate, butyl acetate, chloroform, butanol, methyl isobutyl ketone, or the like.
- TKR459 can be separated from the medium not only by the above-mentioned extraction method using a non-hydrophilic organic solvent but also by the method which comprises contacting the medium with an adsorbent to let TKR459 adsorbed on the adsorbent and desorbing or eluting them with a solvent.
- the adsorbent that can be used includes, for example, activated carbon, cellulose powder, and adsorbent resins.
- solvent a variety of solvents can be selectively used according to the kind and properties of the adsorbent and either singly or in combination.
- an aqueous solution of one or more water-soluble organic solvents such as aqueous acetone, aqueous alcohol, etc.
- aqueous acetone aqueous acetone
- aqueous alcohol aqueous alcohol
- hydrophilic organic solvent such as acetone
- the crude extract of TKR459 from the culture broth can further be purified.
- the purification can be carried out by the conventional techniques for the isolation and purification of hydrophobic antibiotics, for example, by column chromatography or high-performance liquid chromatography, using an absorbent such as silica gel, activated alumina, activated carbon, adsorbent resin, etc.
- an absorbent such as silica gel, activated alumina, activated carbon, adsorbent resin, etc.
- the eluent includes chloroform, ethyl acetate, methanol, acetone, water, etc. and these can be used in combination of two or more than two kinds.
- adsorbents include chemically-derivatized silica gel, such as silica gel derivatives having octadecyl, octyl, or phenyl groups, and polystyrenic porous polymer gels, while the mobile phase that can be used includes aqueous solutions of water-soluble organic solvents, such as aqueous methanol, aqueous acetonitrile, etc.
- TKR459 can each be put to use as such or in the form of a pharmacologically acceptable salt in medicinal applications.
- the salt includes salts of mineral acids such as hydrochloric acid, sulfuric acid, nitric acid, phosphoric acid, hydrofluoric acid, hydrobromic acid, etc., salts of organic acids such as formic acid, acetic acid, tartaric acid, lactic acid, citric acid, fumaric acid, maleic acid, succinic acid, methanesulfonic acid, ethanesulfonic acid, benzenesulfonic acid, toluenesulfonic acid, naphthalenesulfonic acid, camphorsulfonic acid, etc., and salts of alkali metals or alkaline earth metals, such as sodium, potassium, calcium, etc.
- TKR459 or its pharmacologically acceptable salt of the present invention can be administered to animals inclusive of humans either as such or in the form of a pharmaceutical composition containing typically 0.1 to 99.5%, preferably 0.5 to 90% thereof in a pharmaceutically acceptable, non toxic and inert carrier.
- the carrier mentioned above includes solid, semisolid or liquid diluents, fillers, other formulation auxiliaries, etc. and such carriers can be used alone or in combination.
- the above-mentioned pharmaceutical composition is preferably administered in unit dosage forms and can be administered orally, parenterally, topically (e.g. transdermally) or rectally.
- those pharmaceutical compositions should be administered in dosage forms suited for the respective route of administration.
- the dose as an antifungal agent is preferably selected with reference to patient factors such as age and body weight, route of administration, nature and severity of disease, etc.
- the daily dose of the active ingredient for an adult patient is 10 to 2000 mg. While a daily dose lower than the above range may be sufficient in some cases, a dose higher than the range may be required in other cases.
- the daily dosage is preferably administered in several divided doses.
- the oral administration can be made using solid, powdery, or liquid dosage forms such as powders, dilluted powders, tablets, dragees, capsules, drops, sublingual tablets, etc.
- liquid unit dosage forms for subcutaneous, intramuscular, or intravenous administration of typically solutions and suspensions, can be employed.
- These preparations can be manufactured by suspending or dissolving a predetermined amount of TKR459, or a pharmaceutically acceptable salt thereof of the present invention, in a nontoxic liquid carrier suitable for injection, such as an aqueous medium or an oily medium, and sterilizing the resulting suspension or solution.
- the topical administration can be carried out using a variety of topical dosage forms such as liquids, creams, powders, pastes, gels, and ointments. These dosage forms can be manufactured by using a predetermined amount of TKR459 or a pharmacologically acceptable salt thereof of the present invention, in combination with one or more of the perfume, coloring agent, filler, surfactant, humectant, emollient, gelatinizer, carrier, preservative, stabilizer, etc., suitable for topical dosage formulations.
- the rectal administration can be made using, for example, suppositories each mixing a predetermined amount of TKR459, or its pharmacologically acceptable salt of the present invention, with a low-melting solid base such as higher esters, e.g. myristyl palmitate, polyethylene glycol, cacao butter, or a mixture of them.
- a low-melting solid base such as higher esters, e.g. myristyl palmitate, polyethylene glycol, cacao butter, or a mixture of them.
- a loopful of TKR459-strain (FERM BP-6094) from a slant culture was used to inoculate into a 500-ml Erlenmeyer flask containing 100 ml of liquid medium (Difco yeast nitrogen base 0.67% (w/v), glucose 2.0% (w/v)) and incubated on a shaker at 25° C. for 3 days to prepare a seed culture.
- This seed culture 1.0 ml was transferred to 20 Erlenmeyer flasks of 500 ml capacity each containing 120 ml of the same liquid medium as above and incubated (under shaking at 220 rpm) at 25° C. for 8 days.
- the obtained culture broth was centrifuged and the supernatant was separated from cells.
- Methanol (1 L) was added to the cells, the mixture was sufficiently mixed, and the extract was concentrated under reduced pressure.
- Water and butanol (each 300 ml) were added to the resulting residue, and the mixture was sufficiently mixed and extracted with butanol.
- the extract was concentrated under reduced pressure and gave a residue (1016 mg).
- the residue was treated with a extraction with liquid-liquid partition using n-hexane/acetonitril/trifluoroacetic acid (100:100:0.5).
- the lower layer was concentrated, and extracted with methanol to yield a crude extract (207 mg).
- the extract was dissolved in a small volume of methanol and subjected to high-performance liquid chromatography to provide an active fraction.
- the fraction was concentrated under reduced pressure and gave a resiue (83.7 mg).
- the high-performance liquid chromatography was carried out under the following conditions.
- Mass spectrometry was carried out by JMS-DX302 mass spectrometer (manufactured by Jeol Ltd.).
- 1 H-NMR in deuterated dimethyl sulfoxide with dimethyl sulfoxide as reference
- 13 C-NMR in deuterated dimethyl sulfoxide with deuterated dimethyl sulfoxide as reference
- Specific optical rotation in methanol was determined by DIP370 digital polarimeter (manufactured by Jasco Ltd.).
- the purified white powdery product obtained by concentration of the active fraction in said high-performance liquid chromatography under reduced pressure was found by FAB-MS to be a substance with a peak at m/z 448 [M+H]+.
- the purified white powdery product obtained by concentration of the active fraction in said high-performance liquid chromatography under reduced pressure was found to be 23 carbon atoms and one nitrogen atom by 1 H-NMR spectrum, 13 C-NMR spectrum, and their anlyses.
- the purified white powdery product obtained by concentration of the active fraction in said high-performance liquid chromatography under reduced pressure was identified to be TKR459.
- TKR459 was analyzed by reversed-phase partition high-performance liquid chromatography (HPLC) using LC-10A high-performance liquid chromatography (manufactured by Shimadzu). This HPLC analysis was carried out under the following conditions.
- the TKR459 obtained was used to determine antimicrobial spectra against various microorganisms.
- the minimal inhibitory concentration ( ⁇ g/ml) was measured by the liquid medium dilution method as the minimal concentration causing a substantially complete inhibition of micobial growth.
- the results are presented in Table 2.
- the sub-minimal inhibitory concentration ( ⁇ g/ml) was determined as the minimal concentration causing a partial inhibition of micobial growth and shown in the parentheses of Table 2.
- YNBG stands for a medium comprising 0.67% of yeast nitrogen base (manufactured by Difco) and 1.0% of glucose.
- TKR459 the antifungal substance according to the present invention, was active against pathogenic fungi such as Candida albicans, Candida kefyr, Cryptococcus neoformans etc.
- the present invention provides the antifungal substance TKR459 which is of use as clinical medicine, for example in the therapy of fungal infectious diseases, and a method for production of the substance.
Landscapes
- Organic Chemistry (AREA)
- Chemical & Material Sciences (AREA)
- Wood Science & Technology (AREA)
- Life Sciences & Earth Sciences (AREA)
- Engineering & Computer Science (AREA)
- Zoology (AREA)
- Biotechnology (AREA)
- Microbiology (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Health & Medical Sciences (AREA)
- Biochemistry (AREA)
- Bioinformatics & Cheminformatics (AREA)
- General Engineering & Computer Science (AREA)
- General Health & Medical Sciences (AREA)
- Genetics & Genomics (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
Abstract
The present invention has its object to provide a noble antifungal substance which is use of as clinical medicine in the therapy of fungal infectious diseases.
Description
- The present invention relates to TKR459, which is an antibiotic of use as a therapeutic agent for fungal infectious diseases, a method for their production, and microorganisms producing said antibiotic.
- Fungi are known to cause a variety of infectious diseases in man, animals, and plants. In man, for instance, they cause superficial mycosis affecting the skin, oral cavity, etc. and systemicmycosis affecting the viscera, brain, etc. They cause similar infections in pet and domestic animals as well. Furthermore, fungi inflict various hazardous effects on plants such as orchard trees and vegetables.
- As the principal pathogenic fungi causing systemic mycosis in man, those of the genera Candida, Cryptococcus, and Aspergillus, among others, are known. As to superficial mycosis, Candida species affecting the skin, oral cavity, and vagina and Trichophytons infecting the skin of the extremities are regarded as the major pathogenic fungi. Besides those fungi, many other fungi exist in the environment and are suspected to contaminate the animal and vegetable kingdoms.
- As antimycotics of use for the prevention and treatment of such fungal infections and contaminations, only a very few are known. Among them, as therapeutic drugs for systemic mycosis in man and animals, for instance, amphotericin B, flucytosine, miconazole, and fluconazole can be mentioned. However, those compounds are not fully satisfactory in potency, toxic potential, or antifungal spectrum, thus being not impeccable as therapeutic drugs.
- In view of the above-mentioned prior art, the present invention has for its object to provide a novel antibiotic which is of value as a therapeutic agent for fungal infections.
- In their search for a novel antibiotic, the inventors of the present invention isolated a large number of microorganisms from the natural kingdom, isolated the antibiotics they produced, and scrutinized their biological properties. As a result, they discovered that the culture broth of a strain of microorganism of the class Fungi Imperfecti contained an antibiotic having antifungal activity against pathogenic fungi inclusive ofCandida albicans, Candida kefyr, and Cryptococcus neoformans. Accordingly the inventors isolated this antibiotic and studied its physicochemical properties. As a result, they discovered that the above antibiotic is a novel substance having distinct physicochemical characteristics and named it TKR459.
-
- The present invention is further directed to a method of producing the antibiotic TKR459 which comprises culturing a strain of microorganism belonging to Fungi Imperfecti and capable of elaborating said antibiotic TKR459 and then isolating said substance from the resulting culture broth.
- Furthermore, the present invention is directed to a microorganism belonging to Fungi Imperfecti and capable of producing the antibiotic TKR459.
- FIG. 1 is a chart showing the ultraviolet absorption spectrum of the antibiotic TKR459. The ordinate represents wave length (nm) and the abscissa represents absorbance.
- FIG. 2 is a chart showing the infrared absorption spectrum of the antibiotic TKR459. The ordinate represents relative intensity of transmission (%) and the abscissa represents wave numbers (cm−1).
- FIG. 3 is a chart showing the1H-NMR spectrum of the antibiotic TKR459. The ordiante represents intensity of signal and the abscissa represents chemical shift value (ppm).
- FIG. 4 is a chart showing the13C-NMR spectrum of the antibiotic TKR459. The ordiante represents intensity of signal and the abscissa represents chemical shift value (ppm).
- FIG. 5 is a HPLC chart of the antibiotic TKR459 showing its elution position. The ordinate represents the relative intensity of ultraviolet absorption and the abscissa represents retention time (min.).
- The present invention is now described in detail.
- The antibiotic TKR459 of the present invention is represented by the chemical formula (1) described above.
- The antibiotic TKR459 has the following physicochemical characteristics (1), (2), (3), (4), (5) and (6).
- (1) Mass spectrum by FAB-MS gives a peak at m/z 448 [M+H]+;
- (2) The number of carbon atom is 23 and the number of nitrogen atom is 1;
- (3) The specific optical rotaion is [α]D 20+8.1° (C 0.36, methanol);
- (4) The UV spectrum in methanol has no characteristic absorptions;
- (5) The wave numebers of major absorption in the IR spectrum by KBr method are 3400 cm−, 2920 cm−, 2850 cm−, 1680 cm−1, 1470 cm−, 1200 cm−, 1140 cm−, 840 cm−, 800 cm−, and 720 cm−.
- (6) It is soluble in methanol and water, and sparingly soluble in hexane and chloroform.
- Furthermore, TKR459 mentioned above is characterized in that it has the1H-NMR spectrum shown in FIG. 3 and the 13C-NMR spectrum shown in FIG. 4, and in reversed-phase high- performance liquid chromatography, it is eluted at the position indicated in FIG. 5.
- The above-mentioned TKR459 can be produced by growing a strain of microorganism belonging to the class Fungi Imperfecti and capable of producing said TKR459 and then isolating the substance from the resulting culture broth.
- There is no limitation on the strain of microorganism that can be used in the present invention only provided it belongs to the class Fungi Imperfecti and is capable of producing said TKR459. Thus, for example, the fungi TKR459-strain belonging to the class Fungi Imperfecti (hereinafter referred to as the TKR459-strain) can be mentioned.
- The above-mentioned TKR459-strain is a novel strain, and has never described in literatures, and isolated and characterized for the first time by the inventors of the present invention. The strain has the property to produce TKR459 with advantage. The mycological characteristics of this TKR459-strain are now described in detail.
- The colonial colors of said TKR459-strain on various media are shown in Table 1. The descriptions of colors in the table are based on those prescribed in Japanese Industrial Standard (JIS) Z 8102 (1985) and reflect the results of observation on day 14 of culture at 25° C. after inoculation in the respective media.
TABLE 1 Reverse Colony size color diameter Color of of the Texture of Medium (mm) colony colony the colony Malt 13 Dark Dark brown Ropy extract grayish 2.5YR3/2 agar yellow red 10R4/3 Potato 17 Dark rusty Ropy dextrose grayish 2.5YR3/4 agar yellow red 10R4/3 Sabouraud 19 Darkish Darkish Velvety agar yellow yellow 2.5GY8/4 2.5Y8/6 YpSs agar 23 Light Light Velvety yellow yellow 2.5Y9/4 2.5Y9/4 - The above TKR459-strain grows slowly on malt extract agar, potato dextrose agar, and Sabouraud agar etc., giving colonies showing a ropy or velvety surface texture and a elevated center with dense hard mycelia. The conidia of the TKR459-strain are unicellar, have a shape like cylinder or cask whose both sides are round and surface is smooth, and measure 4 to 6×1.5 to 2.5 μm. Lots of conidia are formed or the above media, but the conidia formation style from the conidiophore was unidentified.
- Among the mycological characters of the TKR459-strain, its physiological characteristics are as follows.
- Temperature range for growth: The temperature range for growth is 10 to 30° C. and the optimum range of temperature for growth is about 25° C.
- The pH range for growth: The pH range for growth is
pH 3 to 8 and the optimum range of pH for growth is aboutpH 4 to 7. - When the above mycological characters are compared with the descriptions of the genera of Fungi Imperfecti in Joseph C. Gilman, A Manual of Soil Fungi, Constable and Company Ltd., 1959, and other literatures, the genus of TKR459-strain can not be identified because of unidentification of the conidia formation style.
- However, no report was available on a strain of microorganism having the ability to produce TKR459 among fungi of the class Fungi Imperfecti. Therefore, the inventors of the present invention regarded it as a novel strain and named fungi TKR459 belonging to Fungi Imperfecti. The strain was deposited at National Institute of Bioscience and Human Technology, Agency of Industrial Science and Technology (Address, 1-3, Higashi 1-chome, Tsukuba-shi, Ibaraki, Japan (Zip code 305)) under the accession number of FERM BP-6094 (original date of deposit: Oct. 8, 1996; date of request for transfer to international deposit: Sep. 2, 1997).
- The present invention can be carried into practice not only with the above-mentioned TKR459-strain but also with any spontaneous or artificial mutant of said TKR459-strain or any other strain of microorganism belonging to the class Fungi Imperfecti and capable of producing TKR459.
- In accordance with the present invention, TKR459 is produced by seeding and cultivating a TKR459-producing strain in a nutrient medium. As said nutrients, carbon sources include glucose, fructose, saccharose, starch, dextrin, glycerol, molasses, malt syrup, oils and fats, and organic acids.
- Nitrogen sources as nutrients include organic and inorganic nitrogenous substances such as soybean meal, cotton seed meal, corn steep liquor, casein, peptone, yeast extract, meat extract, wheat germs, urea, amino acids, ammonium salts, etc. Salts as nutrients are various inorganic salts such as salts of sodium, potassium, calcium, magnesium, etc. and salts of phosphoric acid. Those substances can be used independently or in a suitable combination.
- Where necessary, the nutrient medium may be supplemented with heavy metal salts such as iron salts, copper salts, zinc salts, cobalt salts, etc., vitamins such as biotin, vitamin B1, etc., and other organic and inorganic substances which would assist in growth of the microorganism and promote production of TKR459.
- In addition to the above components, an antifoamer and/or a surfactant, for example silicone oil, polyalkylene glycol ethers, etc., can be added to the nutrient medium.
- In cultivating a strain of microorganism capable of producing TKR459 in said nutrient medium, a variety of cultural methods which are generally used in the production of antibiotics by culture of microorganisms can be employed. However, liquid culture, particularly shake culture or submerged aerobic culture, is preferred.
- The cultivation is preferably carried out at 15 to 25%. The pH of the medium may range from
pH 3 to 8 but is preferably aroundpH 5. Regarding the incubation time, generally a sufficient output of the antibiotic can be expected by 6 to 11 days of culture. - By the above cultivation, TKR459 is contained both intracellularly and extracellularly and accumulated in the culture broth. In the present invention, the TKR459 accumulated in the culture broth can be recovered and isolated from the broth by utilizing its physicochemical characteristics and, where necessary, by further purification.
- The above-mentioned isolation can be achieved by extracting the whole broth with a non-hydrophilic organic solvent such as ethyl acetate, butyl acetate, chloroform, butanol, methyl isobutyl ketone, or the like. As an alternative, it is possible to subject the broth to centrifugation or filtration to separate into the medium and cells and isolate the antibiotics from each of the medium and cells.
- TKR459 can be separated from the medium not only by the above-mentioned extraction method using a non-hydrophilic organic solvent but also by the method which comprises contacting the medium with an adsorbent to let TKR459 adsorbed on the adsorbent and desorbing or eluting them with a solvent. The adsorbent that can be used includes, for example, activated carbon, cellulose powder, and adsorbent resins. As the above-mentioned solvent, a variety of solvents can be selectively used according to the kind and properties of the adsorbent and either singly or in combination. Thus, an aqueous solution of one or more water-soluble organic solvents, such as aqueous acetone, aqueous alcohol, etc., canbe employed. For isolation of TKR459 from the microorganisms, the extraction technique using a hydrophilic organic solvent such as acetone can be employed.
- In the present invention, the crude extract of TKR459 from the culture broth can further be purified. The purification can be carried out by the conventional techniques for the isolation and purification of hydrophobic antibiotics, for example, by column chromatography or high-performance liquid chromatography, using an absorbent such as silica gel, activated alumina, activated carbon, adsorbent resin, etc. In case of using silica gel column chromatography, the eluent includes chloroform, ethyl acetate, methanol, acetone, water, etc. and these can be used in combination of two or more than two kinds.
- In case of using high-performance liquid chromatography, adsorbents include chemically-derivatized silica gel, such as silica gel derivatives having octadecyl, octyl, or phenyl groups, and polystyrenic porous polymer gels, while the mobile phase that can be used includes aqueous solutions of water-soluble organic solvents, such as aqueous methanol, aqueous acetonitrile, etc.
- TKR459 can each be put to use as such or in the form of a pharmacologically acceptable salt in medicinal applications. There is no particular limitation on the type of pharmacologically acceptable salt. Thus, the salt includes salts of mineral acids such as hydrochloric acid, sulfuric acid, nitric acid, phosphoric acid, hydrofluoric acid, hydrobromic acid, etc., salts of organic acids such as formic acid, acetic acid, tartaric acid, lactic acid, citric acid, fumaric acid, maleic acid, succinic acid, methanesulfonic acid, ethanesulfonic acid, benzenesulfonic acid, toluenesulfonic acid, naphthalenesulfonic acid, camphorsulfonic acid, etc., and salts of alkali metals or alkaline earth metals, such as sodium, potassium, calcium, etc.
- When administering TKR459 or its pharmacologically acceptable salt of the present invention, as a pharmaceutical, they can be administered to animals inclusive of humans either as such or in the form of a pharmaceutical composition containing typically 0.1 to 99.5%, preferably 0.5 to 90% thereof in a pharmaceutically acceptable, non toxic and inert carrier.
- The carrier mentioned above includes solid, semisolid or liquid diluents, fillers, other formulation auxiliaries, etc. and such carriers can be used alone or in combination.
- The above-mentioned pharmaceutical composition is preferably administered in unit dosage forms and can be administered orally, parenterally, topically (e.g. transdermally) or rectally. Of course, those pharmaceutical compositions should be administered in dosage forms suited for the respective route of administration.
- For administration of TKR459, or its pharmacologically acceptable salt, as a drug, the dose as an antifungal agent is preferably selected with reference to patient factors such as age and body weight, route of administration, nature and severity of disease, etc. Usually in man, however, the daily dose of the active ingredient for an adult patient is 10 to 2000 mg. While a daily dose lower than the above range may be sufficient in some cases, a dose higher than the range may be required in other cases. When a high dose is used, the daily dosage is preferably administered in several divided doses.
- The oral administration can be made using solid, powdery, or liquid dosage forms such as powders, dilluted powders, tablets, dragees, capsules, drops, sublingual tablets, etc.
- For the parenteral administration, liquid unit dosage forms for subcutaneous, intramuscular, or intravenous administration, of typically solutions and suspensions, can be employed. These preparations can be manufactured by suspending or dissolving a predetermined amount of TKR459, or a pharmaceutically acceptable salt thereof of the present invention, in a nontoxic liquid carrier suitable for injection, such as an aqueous medium or an oily medium, and sterilizing the resulting suspension or solution.
- The topical administration (e.g. transdermal administration) can be carried out using a variety of topical dosage forms such as liquids, creams, powders, pastes, gels, and ointments. These dosage forms can be manufactured by using a predetermined amount of TKR459 or a pharmacologically acceptable salt thereof of the present invention, in combination with one or more of the perfume, coloring agent, filler, surfactant, humectant, emollient, gelatinizer, carrier, preservative, stabilizer, etc., suitable for topical dosage formulations.
- The rectal administration can be made using, for example, suppositories each mixing a predetermined amount of TKR459, or its pharmacologically acceptable salt of the present invention, with a low-melting solid base such as higher esters, e.g. myristyl palmitate, polyethylene glycol, cacao butter, or a mixture of them.
- The following examples are further illustrative of the present invention, but by no means limitative of the scope of the invention.
- A loopful of TKR459-strain (FERM BP-6094) from a slant culture was used to inoculate into a 500-ml Erlenmeyer flask containing 100 ml of liquid medium (Difco yeast nitrogen base 0.67% (w/v), glucose 2.0% (w/v)) and incubated on a shaker at 25° C. for 3 days to prepare a seed culture. This seed culture 1.0 ml was transferred to 20 Erlenmeyer flasks of 500 ml capacity each containing 120 ml of the same liquid medium as above and incubated (under shaking at 220 rpm) at 25° C. for 8 days. The obtained culture broth was centrifuged and the supernatant was separated from cells. Methanol (1 L) was added to the cells, the mixture was sufficiently mixed, and the extract was concentrated under reduced pressure. Water and butanol (each 300 ml) were added to the resulting residue, and the mixture was sufficiently mixed and extracted with butanol. The extract was concentrated under reduced pressure and gave a residue (1016 mg). The residue was treated with a extraction with liquid-liquid partition using n-hexane/acetonitril/trifluoroacetic acid (100:100:0.5). The lower layer was concentrated, and extracted with methanol to yield a crude extract (207 mg). The extract was dissolved in a small volume of methanol and subjected to high-performance liquid chromatography to provide an active fraction. The fraction was concentrated under reduced pressure and gave a resiue (83.7 mg). The high-performance liquid chromatography was carried out under the following conditions.
- Apparatus: LC6B (manufactured by Shimadzu)
- Column: YMC pack C18 (2.0 cm×25 cm) (manufactured by YMC)
- Mobile phase: 25 to 100% (v/v) of methanol containing 0.05% trifluoroacetic acid
- The residue was dissolved in 0.4 ml of methanol and subjected to high-performance liquid chromatography to give an active fraction. This fraction was concentrated under reduced pressure to provide 9.3 mg of pure TKR459 as white powder. This high-performance liquid chromatography was carried out under the following conditions.
- Apparatus: LC8A (manufactured by Shimadzu)
- Column: YMC pack C18 (2.0 cm×25 cm) (manufactured by YMC)
- Mobile phase: 0.05% trifluoroacetic acid-containing 45% (v/v) acetonitrile/water
- Physicochemical Properties
- Mass spectrometry was carried out by JMS-DX302 mass spectrometer (manufactured by Jeol Ltd.).1H-NMR (in deuterated dimethyl sulfoxide with dimethyl sulfoxide as reference) and 13C-NMR (in deuterated dimethyl sulfoxide with deuterated dimethyl sulfoxide as reference) were performed by JNM-A500 nuclear magnetic resonance spectrometer (manufactured by Jeol Ltd.). Specific optical rotation (in methanol) was determined by DIP370 digital polarimeter (manufactured by Jasco Ltd.).
- Ultraviolet spectrophotometry (in methanol) was carried out by UV-250 self-recording spectrophotometer (manufactured by Shimadzu), and infrared absorption spectrometry (KBr method) was by 270-30 infrared spectrophotometer (manufactured by Hitachi). Physicochemical properties of the substance TKR459 were described below.
- (1) Mass Spectrometry
- The purified white powdery product obtained by concentration of the active fraction in said high-performance liquid chromatography under reduced pressure was found by FAB-MS to be a substance with a peak at m/z 448 [M+H]+.
- (2) Number of Carbon and Nitrogen Atoms
- The purified white powdery product obtained by concentration of the active fraction in said high-performance liquid chromatography under reduced pressure was found to be 23 carbon atoms and one nitrogen atom by1H-NMR spectrum, 13C-NMR spectrum, and their anlyses.
- The1H-NMR spectrum and 13C-NMR spectrum of this product are presented in FIG. 3 and FIG. 4, respectively.
- (3) Specific Optical Rotation
- The specific optical rotation in methanol of the purified white powdery product obtained by concentration of the active fraction in said high-performance liquid chromatography under reduced pressure was found to be [α]D 20+8.1° (CO.36,methanol)
- (4) Ultraviolet Absorption Spectrum
- The UV absorption in methanol of the purified white powdery product obtained by concentration of the active fraction in said high-performance liquid chromatography under reduced pressure was found to be no characteritic absorption.
- The UV absorption spectrum is shown in FIG. 1.
- (5) Infrared Absorption Spectrum
- The IR spectrophotometric characterization (KBr method) of the purified white powdery product obtained by concentration of the active fraction in said high-performance liquid chromatography under reduced pressure revealed the following numbers of wave length of major absorption.
- IR (KBr) (cm−1): 3400, 2920, 2850, 1680, 1470, 1200, 1140, 840, 800, 720.
- The IR absorption spectrum is shown in FIG. 2.
- The above powder was soluble in methanol and water, but sparingly soluble in chloroform and hexane.
- Based on the above analyses, the purified white powdery product obtained by concentration of the active fraction in said high-performance liquid chromatography under reduced pressure was identified to be TKR459.
- The above TKR459 was analyzed by reversed-phase partition high-performance liquid chromatography (HPLC) using LC-10A high-performance liquid chromatography (manufactured by Shimadzu). This HPLC analysis was carried out under the following conditions.
- Column: CAPCELLPAK C18 (6 mm×150 mm) (manufactured by Shiseido)
- Mobile phase: 0.05% trifluoroacetic acid-containing 40% (v/v) acetonitrile/water
- Column temperature: 40° C.
- Detection UV wave length: 220 nm
- As a result, the above TKR459 was found to be eluted in the position indicated in FIG. 5.
- Biological Characteristics
- The TKR459 obtained was used to determine antimicrobial spectra against various microorganisms. The minimal inhibitory concentration (μg/ml) was measured by the liquid medium dilution method as the minimal concentration causing a substantially complete inhibition of micobial growth. The results are presented in Table 2. The sub-minimal inhibitory concentration (μg/ml) was determined as the minimal concentration causing a partial inhibition of micobial growth and shown in the parentheses of Table 2. In the table, YNBG stands for a medium comprising 0.67% of yeast nitrogen base (manufactured by Difco) and 1.0% of glucose.
TABLE 2 Minimal inhibitory Test strain Medium concentration (μg/ml) Candida albicans YNBG 0.78 TIMM0136 Candida kefyr YNBG 0.78 (0.39) TIMM0301 Cryptococcus neoformans YNBG 3.13 TIMM0354 - It is apparent from Table 2 that TKR459, the antifungal substance according to the present invention, was active against pathogenic fungi such asCandida albicans, Candida kefyr, Cryptococcus neoformans etc.
- Intraperitoneal administration of the TKR459 obtained above at the dose of 100 mg/kg to ICR mice caused no toxic signs.
- As described above, the present invention provides the antifungal substance TKR459 which is of use as clinical medicine, for example in the therapy of fungal infectious diseases, and a method for production of the substance.
Claims (3)
2. A method for producing an antibiotic TKR459, which comprises cultivating a strain of microorganism belonging to the class Fungi Imperfecti and capable of producing TKR459 and then isolating the objective antibiotic from the resulting culture broth.
3. A microorganism belonging to the class Fungi Imperfecti and capable of producing an antibiotic TKR459.
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US09/731,041 US6337410B2 (en) | 1996-11-25 | 2000-12-07 | Antibiotic TKR459, production method, and microorganism |
Applications Claiming Priority (5)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
JP33041296 | 1996-11-25 | ||
JP8-330412 | 1996-11-25 | ||
JPHEI-8-330412 | 1996-11-25 | ||
US30875399A | 1999-06-22 | 1999-06-22 | |
US09/731,041 US6337410B2 (en) | 1996-11-25 | 2000-12-07 | Antibiotic TKR459, production method, and microorganism |
Related Parent Applications (3)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/JP1997/004271 Continuation-In-Part WO1998023767A1 (en) | 1996-11-25 | 1997-11-25 | Antibiotic tkr 459, production method, and microorganism |
US30875399A Continuation-In-Part | 1996-11-25 | 1999-06-22 | |
US09308753 Continuation-In-Part | 1999-06-22 |
Publications (2)
Publication Number | Publication Date |
---|---|
US20010021520A1 true US20010021520A1 (en) | 2001-09-13 |
US6337410B2 US6337410B2 (en) | 2002-01-08 |
Family
ID=26573520
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
US09/731,041 Expired - Fee Related US6337410B2 (en) | 1996-11-25 | 2000-12-07 | Antibiotic TKR459, production method, and microorganism |
Country Status (1)
Country | Link |
---|---|
US (1) | US6337410B2 (en) |
Families Citing this family (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
IL271777B2 (en) | 2017-07-07 | 2024-09-01 | Epicentrx Inc | Compositions for parenteral administration of therapeutic agents |
Family Cites Families (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JPH0613499B2 (en) * | 1985-03-29 | 1994-02-23 | 武田薬品工業株式会社 | Patchoulide and its manufacturing method |
JPH05155877A (en) * | 1991-08-15 | 1993-06-22 | Kaiyo Bio Technol Kenkyusho:Kk | Novel substances: urauchimycin a and urauchimycin b and production thereof |
JPH05271215A (en) * | 1992-03-27 | 1993-10-19 | Meiji Milk Prod Co Ltd | New polyene macrolide compound and antifungal agent containing the same as active ingredient |
-
2000
- 2000-12-07 US US09/731,041 patent/US6337410B2/en not_active Expired - Fee Related
Also Published As
Publication number | Publication date |
---|---|
US6337410B2 (en) | 2002-01-08 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
KR100333017B1 (en) | Polycyclic anthelmintic agent, its preparation, its preparation, and compositions containing it | |
EP1002793B1 (en) | Physiologically active substances tkr2449, process for producing the same, and microorganism | |
US6333305B1 (en) | Antibiotic TKR2999, process for the preparation thereof and microbe | |
US6337410B2 (en) | Antibiotic TKR459, production method, and microorganism | |
US6380245B1 (en) | Antibiotics TKR1912-I and TKR1912-II and process for producing the same | |
EP0937718B1 (en) | Antibiotic tkr2648 and process for producing the same | |
EP0955376A1 (en) | Antibiotic tkr 459, production method, and microorganism | |
US6103767A (en) | Physiologically active substances TKR1785's, process for the preparation thereof, and microbe | |
US5801172A (en) | Antifungal agent from sporomiella minimoides | |
US5770587A (en) | Antifungal agents | |
US5091413A (en) | Antibiotic agent | |
JP4256019B2 (en) | Novel antibiotic TKR2462 and method for producing the same | |
US5702929A (en) | Antifungal agent | |
US5712151A (en) | Antifungal agent | |
JPH09249680A (en) | Antibiotic tkr842, its production and microorganism | |
GB2306480A (en) | Antifungal agents | |
JP2000316592A (en) | New antibiotic tkr 2993 and its production | |
WO1997026367A1 (en) | Antibiotics tkr 400-a and tkr 400-b and processes for producing these | |
JPH0925286A (en) | Antibiotic substance tkr2554 and its production | |
JP2000290293A (en) | Antifungal active compound | |
GB2306474A (en) | Antifungal agent |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
AS | Assignment |
Owner name: TAKARA SHUZO CO., LTD., JAPAN Free format text: ASSIGNMENT OF ASSIGNORS INTEREST;ASSIGNORS:TAKESAKO, KAZUTOH;UENO, MITSUHIRO;AWAZU, NAOYUKI;AND OTHERS;REEL/FRAME:011676/0879 Effective date: 20010115 |
|
FEPP | Fee payment procedure |
Free format text: PAYOR NUMBER ASSIGNED (ORIGINAL EVENT CODE: ASPN); ENTITY STATUS OF PATENT OWNER: LARGE ENTITY |
|
FPAY | Fee payment |
Year of fee payment: 4 |
|
REMI | Maintenance fee reminder mailed | ||
LAPS | Lapse for failure to pay maintenance fees | ||
STCH | Information on status: patent discontinuation |
Free format text: PATENT EXPIRED DUE TO NONPAYMENT OF MAINTENANCE FEES UNDER 37 CFR 1.362 |
|
FP | Lapsed due to failure to pay maintenance fee |
Effective date: 20100108 |